Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2792171 | 0.88 | ROCK2 (0.50) | MEN1KMT2AALDH1A1SMN1; SMN2PKM | |
| SCHEMBL2793503 | 0.88 | ROCK2 (0.54) | MEN1KMT2AALDH1A1SMN1; SMN2PKM | |
| SCHEMBL2794381 | 0.86 | ROCK2 (0.64) | MEN1KMT2AALDH1A1SMN1; SMN2PKM | |
| SCHEMBL30926974 | 0.85 | MEN1 (0.74) | MEN1KMT2AALDH1A1SMN1; SMN2PKM | |
| SCHEMBL27179653 | 0.85 | MEN1 (0.74) | MEN1KMT2AALDH1A1SMN1; SMN2PKM | |
| SCHEMBL3503302 | 0.83 | MEN1 (0.65) | MEN1KMT2AALDH1A1SMN1; SMN2PKM | |
| SCHEMBL2792854 | 0.83 | ROCK2 (0.60) | MEN1KMT2AALDH1A1SMN1; SMN2PKM | |
| SCHEMBL2793159 | 0.82 | KMT2A (0.52) | MEN1KMT2ASMN1; SMN2LMNAROCK2 | |
| SCHEMBL2796143 | 0.81 | ROCK2 (0.55) | MEN1KMT2ASMN1; SMN2MAPTNAMPT | |
| SCHEMBL2795473 | 0.81 | NT5E (0.66) | MEN1KMT2AALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | MEN1 1522/4885KMT2A 1918/4885ALDH1A1 2175/4885 |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | MEN1 1522/4885KMT2A 1918/4885ALDH1A1 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.